Q-omics provides the consensus-scored RPL22P22 profile across patient tissues and cancer cell-line models. RPL22P22 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Additionally, RPL22P22 RNA expression shows 5,991 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD as cancer lineages where RPL22P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.